Home / For clinicians / Conditions / Cardiology
Cardiology
2 conditions and 5 prescribing guides so far.
By specialty and condition
Each condition page compares its drugs side by side and lists FDA decisions, label changes and open trials.
Prescribing guides
The first 90 days from the prescriber's side, built from the current label, the drugmaker's program and one public insurer policy.
ATTR amyloidosis with cardiomyopathy (ATTR-CM)
Amvuttra (vutrisiran)Dosing, Vitamin A and PA CriteriaNo REMS. A Start Form to Alnylam Assist signed by patient and prescriber, which also carries the prescription; prior authorization; a site of care, from office or infusion center to home nursing where coverage allows; administration by a healthcare professional.Attruby (acoramidis)Dosing, Interactions and PA CriteriaNo REMS; specialty dispensing through Orsini, PANTHERx Rare or select health system pharmacies after prior authorization; ForgingBridges Start Form and patient consent faxed to 1-877-738-0545, or eRx to RareMed Solutions.Vyndamax (tafamidis)Dosing, Conversion and PA CriteriaNo REMS; prior authorization where the plan requires it, a specialty pharmacy in the plan's network, and shipment to the patient's home once approved.Obstructive hypertrophic cardiomyopathy
Camzyos (mavacamten)REMS, Echo Schedule and PA CriteriaREMS-certified prescriber and pharmacy, Patient Enrollment Form carrying the baseline echo with LVEF 55% or higher, a negative pregnancy test where it applies, and the pharmacy's medication review; the REMS authorizes every fill.Myqorzo (aficamten)REMS, Echo Titration and PA CriteriaREMS-certified prescriber and pharmacy, Patient Guide counseling, a baseline echocardiogram with LVEF 55% or higher, and a Patient Enrollment Form signed by patient and prescriber, with treatment started within 3 months of the form; the REMS authorizes every fill.